Boehringer Ingelheim posts completed bioequivalence trial of two pramipexole tablet formulations
A Phase 1 crossover study comparing Sifrol and Mirapex pramipexole tablets in healthy volunteers is listed as completed, with results tracking pharmacokinetics at steady state.
Boehringer Ingelheim's registry activity for the week centers on a single completed early-phase pharmacokinetics study.
- **Pramipexole tablets (Sifrol® vs Mirapex®), Phase 1, healthy volunteers**: The trial is listed as completed, with the goal to find out whether pramipexole tablets made at two different production sites are handled in the same way by the body.1 The study was an open-label, randomized, multiple-dose, two-way crossover trial with 25 participants enrolled1, primarily measuring Area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ (AUCτ,ss) and Maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ (Cmax,ss)1. The record lists primary completion on 2026-09-10 and study completion on 2026-09-22, both actual dates.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.